Bicycle Therapeutics plc (BCYC) is a Biotechnology company in the Healthcare sector, currently trading at $5.06. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is BCYC = $11 (+117.4% upside).
Valuation: BCYC trades at a trailing Price-to-Earnings (P/E) of -1.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.23.
Financials: revenue is $73M, +74.4%/yr average growth. Net income is $219M (loss), growing at -27.8%/yr. Net profit margin is -301.7% (negative). Gross margin is 100% (+25.5 pp trend).
Balance sheet: total debt is $18M against $610M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 11.02 (strong liquidity). Debt-to-assets is 2.4%. Total assets: $718M.
Analyst outlook: 17 / 21 analysts rate BCYC as buy (81%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).
